All In Biotech

Drug Trial Radar · NCT07874620

A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain

A Randomized, Double-Blind, Multiple-Dose Study to Assess the Ability of Cebranopadol to Suppress Withdrawal Signs and Symptoms in Adults With Chronic Pain Who Are Physically Dependent on Opioids

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Mar 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Adneuris Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids. Participants whose physical dependence is confirmed will be assigned by chance to one of two cebranopadol dose regimens or matching placebo. The study will also evaluate pain, safety and tolerability, and cebranopadol pharmacokinetics.

Conditions

  • Chronic Pain
  • Pain
  • Opioid Withdrawal (Disorder)
  • Opioid Use Disorder

Interventions

  • CebranopadolDrug

    Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.

  • CebranopadolDrug

    Administration orally twice daily on Days 1 and 2 and according to the assigned regimen.

  • PlaceboDrug

    Administration orally twice daily on Day 1 and 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Opiate Withdrawal Scale (COWS) Total Score Maximum Effect (Emax) from 0 to 48 hoursTime frame: From first study-drug administration through 48 hours after the first dose]

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • 001127

    North Canton, Ohio · Recruiting

  • 00113

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.